Rapid Micro Biosystems ends strategic review; no binding offers received for sale

RAPID MICRO BIOSYSTEMS, INC.

Board concludes review of strategic alternatives that began August 2022; no parties submitted binding offers to acquire all outstanding shares.
Company to continue executing current strategy: enhance commercial execution, product development, expand Growth Direct market.
As of Q3 2022, cash, cash equivalents and investments total $150.1M with no debt; cash runway expected into 2026.
CEO cites recent actions to right-size cost structure and manage cash to secure long runway.
Board confident in management's strategy to drive improved performance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.